is the fda stopping the sale of tirzepatide moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified Last week @fda sends out

Tirzepatide's ability to safely achieve normoglycemia in a substantial subset of patients suggests that disease remission may now be a realistic therapeutic objective, particularly for those treated earlier in their disease course

It calls that pattern self-limiting while asking readers to contact a provider if it persists

Product Monographs are documents designed to provide medical professionals and patients with all relevant information on the uses, dosages and risks associated with pharmaceutical drugs

How GLP-1 agonists work in the body Ozempics effects stem from its glucagon-like peptide-1 (GLP-1) receptor agonist role